ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 123 filers reported holding ROYALTY PHARMA PLC in Q2 2020. The put-call ratio across all filers is 0.58 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $241,208,570 | -10.2% | 8,887,567 | +1.7% | 0.03% | -6.9% |
| Q2 2023 | $268,549,912 | -14.0% | 8,736,171 | +0.7% | 0.03% | -23.7% |
| Q1 2023 | $312,436,000 | +93739.6% | 8,671,563 | +2.9% | 0.04% | -13.6% |
| Q4 2022 | $332,947 | -99.9% | 8,424,747 | +1.1% | 0.04% | -8.3% |
| Q3 2022 | $334,764,000 | +4.1% | 8,331,597 | +8.9% | 0.05% | +6.7% |
| Q2 2022 | $321,522,000 | +48.4% | 7,647,985 | +37.6% | 0.04% | +73.1% |
| Q1 2022 | $216,592,000 | +0.2% | 5,559,388 | +2.5% | 0.03% | +4.0% |
| Q4 2021 | $216,075,000 | +12.5% | 5,422,203 | +2.0% | 0.02% | +4.2% |
| Q3 2021 | $192,138,000 | -35.9% | 5,316,482 | -27.3% | 0.02% | -33.3% |
| Q2 2021 | $299,842,000 | +18.6% | 7,315,001 | +26.2% | 0.04% | +5.9% |
| Q1 2021 | $252,790,000 | -16.9% | 5,795,267 | -4.7% | 0.03% | -24.4% |
| Q4 2020 | $304,322,000 | +93.1% | 6,080,359 | +62.1% | 0.04% | +73.1% |
| Q3 2020 | $157,590,000 | -12.8% | 3,751,236 | +0.7% | 0.03% | -25.7% |
| Q2 2020 | $180,797,000 | – | 3,723,924 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |